Roles of Experimentally Evolved Vaccinia Mutations in Antagonizing Cell Defenses
Roles of Experimentally Evolved Vaccinia Mutations in Antagonizing Cell Defenses
批准号:
8769973
负责人:
ADAM P. GEBALLE
金额:
$22.0万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-15 至 2016-04-30
关键词:
AffectAntiviral AgentsBackBiological AssayBiological ModelsCellsCercopithecus pygerythrusConflict (Psychology)CoupledCytomegalovirusDNA VirusesDNA-Directed RNA PolymeraseDefectDetectionDouble-Stranded RNAEvolutionFibroblastsFrameshift MutationGene AmplificationGenesGeneticGenetic TranscriptionHealthHost DefenseHumanImmune responseImmunizationImmunoblottingImmunofluorescence ImmunologicImmunoprecipitationInfectionIsatinLabelMacaca mulattaMass Spectrum AnalysisMedicalMessenger RNAMetabolic PathwayMissense MutationModelingMolecularMonitorMutationOncolyticPathway interactionsPharmaceutical PreparationsPhosphorylationPoxviridaeProductionProteinsRNARNA BindingRaceRegulationResistanceRibonucleasesRiskRoleSerial PassageSeriesSmallpox VirusesSystemTechnologyTestingThiosemicarbazonesTranscriptTropismVacciniaVaccinia virusVacciniumVariantViralViral ProteinsVirusVirus Replicationarmbasecell typeclinical applicationdeep sequencinggene functionimprovedinsightmutantoncolytic vectorpathogenprotein expressionprotein kinase Rprotein phosphatase inhibitor-2public health relevanceresearch studytransmission processvector vaccineviral RNA
中文摘要
描述(由申请人提供):除了它们作为病原体、疫苗载体和溶瘤剂的医学重要性外,痘病毒还提供了易于处理的模型系统,用于发现病毒与其寄生的宿主细胞之间潜在的基本分子和进化机制。这些冲突促使宿主和病毒迅速进化
蛋白质,并可能对病毒传播造成物种障碍。其中一种情况是dsRNA激活的蛋白激酶R(PKR)途径,它具有广泛的抗病毒活性,但可以被各种病毒因子以物种特有的方式阻断。实验进化与深度测序技术相结合,为揭示PKR及其拮抗者之间军备竞赛的新因素和新机制提供了强有力的策略。例如,牛痘病毒(VV)突变体连续传代,其编码的拮抗剂仅弱地阻断一种细胞类型中的PKR,产生的后代病毒不仅能够在用于连续传代的细胞中更有效地复制,而且在其他物种的细胞中也能够更有效地复制。进一步的研究表明,编码弱拮抗剂的基因的扩增或另外两个VV基因A24R和A35R的突变(这两个基因以前都没有被认为是PKR途径的调节器)显著地改善了VV在多个物种的细胞中的复制。这些研究旨在阐明A24R和A35R突变使VV战胜PKR和相关宿主防御系统的机制。因此,该项目将揭示这些保守的痘病毒基因的功能以及PKR途径及其VV拮抗剂的作用和调节。更广泛地说,这些结果将有助于理解大型DNA病毒如何进化来克服宿主防御,并将对理解病毒跨物种传播的风险和障碍产生影响。
英文摘要
DESCRIPTION (provided by applicant): In addition to their medical importance as pathogens, vaccine vectors and oncolytic agents, poxviruses offer tractable model systems for discovering fundamental molecular and evolutionary mechanisms underlying the "arms races" between viruses and the host cells they parasitize. These conflicts drive rapid evolution of host and viral
proteins and can create species barriers to viral transmission. One such case is the dsRNA-activated protein kinase R (PKR) pathway, which has broad antiviral activity but can be blocked, in a species-specific manner, by a variety of viral factors. Experimental evolution coupled with deep sequencing technology offers a powerful strategy for uncovering new factors and mechanisms underlying the arms race between PKR and its antagonists. For example, serial passage of a vaccinia virus (VV) mutant that encodes an antagonist that only weakly blocks PKR in one cell type yielded progeny viruses that were able to replicate much more efficiently not only in the cells used for the serial passage but also in cells from other species. Further studies revealed that amplification of the gene encoding the weak antagonist or mutations in either of two other VV genes, A24R and A35R, neither of which has previously been implicated as a modulator of the PKR pathway, dramatically improves VV replication in cells from multiple species. The proposed studies aim to elucidate the mechanisms by which mutations in A24R and A35R enable VV overcome the PKR and related host defense systems. Thus, this project will reveal new insights into the functions of these conserved poxvirus genes and into the roles and regulation of the PKR pathway and its VV antagonists. More generally, the results will aid in understanding how large DNA viruses can evolve to overcome host defenses and will have implications for understanding the risks and barriers to cross species transmission of viruses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evolution and mechanism of restriction of herpesviruses by MxB
-
批准号:10667144
-
项目类别:
-
资助金额:$26.4万
-
财政年份:2023
-
负责人:ADAM P. GEBALLE
-
依托单位:
Roles and regulation of polyamines during HCMV infection
-
批准号:10308688
-
项目类别:
-
资助金额:$4.91万
-
财政年份:2020
-
负责人:ADAM P. GEBALLE
-
依托单位:
Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses
-
批准号:10630815
-
项目类别:
-
资助金额:$44.01万
-
财政年份:2020
-
负责人:ADAM P. GEBALLE
-
依托单位:
Roles and regulation of polyamines during HCMV infection
-
批准号:10593450
-
项目类别:
-
资助金额:$17.09万
-
财政年份:2020
-
负责人:ADAM P. GEBALLE
-
依托单位:
Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses
-
批准号:10376227
-
项目类别:
-
资助金额:$44.01万
-
财政年份:2020
-
负责人:ADAM P. GEBALLE
-
依托单位:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
-
批准号:10434692
-
项目类别:
-
资助金额:$62.92万
-
财政年份:2019
-
负责人:ADAM P. GEBALLE
-
依托单位:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
-
批准号:10005407
-
项目类别:
-
资助金额:$65.57万
-
财政年份:2019
-
负责人:ADAM P. GEBALLE
-
依托单位:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
-
批准号:10188583
-
项目类别:
-
资助金额:$63.6万
-
财政年份:2019
-
负责人:ADAM P. GEBALLE
-
依托单位:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
-
批准号:10626882
-
项目类别:
-
资助金额:$62.33万
-
财政年份:2019
-
负责人:ADAM P. GEBALLE
-
依托单位:
Roles of Experimentally Evolved Vaccinia Mutations in Antagonizing Cell Defenses
-
批准号:8848032
-
项目类别:
-
资助金额:$26.4万
-
财政年份:2014
-
负责人:ADAM P. GEBALLE
-
依托单位:
Viral immunomodulation and rational CMV vaccine design
-
批准号:8238125
-
项目类别:
-
资助金额:$46.1万
-
财政年份:2003
-
负责人:ADAM P. GEBALLE
-
依托单位:
Viral immunomodulation and rational CMV vaccine design
-
批准号:8435304
-
项目类别:
-
资助金额:$51.46万
-
财政年份:2003
-
负责人:ADAM P. GEBALLE
-
依托单位:
Viral immunomodulation and rational CMV vaccine design
-
批准号:8467815
-
项目类别:
-
资助金额:$6.27万
-
财政年份:2003
-
负责人:ADAM P. GEBALLE
-
依托单位:
Viral immunomodulation and rational CMV vaccine design
-
批准号:8113657
-
项目类别:
-
资助金额:$47.98万
-
财政年份:2003
-
负责人:ADAM P. GEBALLE
-
依托单位:
Translation termination a chemotherapeutic target?
-
批准号:6334292
-
项目类别:
-
资助金额:$17.3万
-
财政年份:2001
-
负责人:ADAM P. GEBALLE
-
依托单位:
Translation termination a chemotherapeutic target?
-
批准号:6515089
-
项目类别:
-
资助金额:$17.3万
-
财政年份:2001
-
负责人:ADAM P. GEBALLE
-
依托单位:
TRANSLATIONAL CONTROL OF CYTOMEGALOVIRUS GENE EXPRESSION
-
批准号:2063485
-
项目类别:
-
资助金额:$1.81万
-
财政年份:1988
-
负责人:ADAM P. GEBALLE
-
依托单位:
TRANSLATIONAL CONTROL OF CYTOMEGALOVIRUS GENE EXPRESSION
-
批准号:3454756
-
项目类别:
-
资助金额:$12.86万
-
财政年份:1988
-
负责人:ADAM P. GEBALLE
-
依托单位:
Translational Control of Cytomegalovirus Gene Expression
-
批准号:6730513
-
项目类别:
-
资助金额:$38.34万
-
财政年份:1988
-
负责人:ADAM P. GEBALLE
-
依托单位:
TRANSLATIONAL CONTROL OF CYTOMEGALOVIRUS GENE EXPRESSION
-
批准号:2671927
-
项目类别:
-
资助金额:$31.74万
-
财政年份:1988
-
负责人:ADAM P. GEBALLE
-
依托单位:
海外基金